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How Much Statin
Intervention Is Enough?*
John C. LaRosa, MD
Brooklyn, New York
Numerous large clinical trials have now demonstrated that
lowering low-density lipoprotein (LDL) levels with statins
is highly beneficial (1). The intervention results in a signif-
icantly lower risk of both fatal and nonfatal coronary and
cerebrovascular events in middle-aged men of European
descent, who comprise the majority of patients studied.
Available evidence expanding those findings to other pop-
ulation groups (women of all ages, younger and older men,
and men and women of non-European lineage) is variable,
often highly suggestive, but not indisputably definitive.
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Clinical trials directed at answering the question “how
low an LDL is low enough?” have not clearly identified an
LDL level below which there is no further lowering of
vascular risk. Recent trials, however, have suggested that if
such an LDL level exists, it is much lower than might have
been earlier expected (2,3).
The paper by Lee et al. (4) in this issue of the Journal is
an indirect attempt to explore this issue further. It has
several shortcomings.
1. It is not a randomized trial but rather an observational
comparison of patients after a myocardial infarction
(MI) with LDL levels at the time of presentation
lower than 70 mg/dl and who subsequently were, or
were not, treated with statins.
2. Beyond the index lipid levels, no further LDL (or
other) levels are reported.
3. The index LDL level was drawn within 24 h of the
onset of MI symptoms to avoid the confounding effect
of an acute MI dramatically, but temporarily, lowering
LDL levels. Even though the index LDL was ob-
tained with 24 h of the MI, the reported index LDL
levels may not be representative of the patient’s free-
living levels.
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This report joins others (5) suggesting that statin therapy
may have significant benefits on vascular events in the
immediate post-MI period and in the first year of follow-up,
even in those whose LDL levels are already quite low (6).
These reports cannot indicate if that effect is mediated
through LDL lowering, a “pleiotropic” effect, or both.
These findings raise the possibility that a clinical trial of
statin therapy with a placebo arm might still be ethically
acceptable, although careful monitoring of LDL levels (with
statin intervention if LDL levels rose above current LDL
targets) would be required.
Such a trial could also address the lingering concern that
very low LDL levels might themselves be a risk for the
development of some other serious, nonvascular disorders
(7). Currently, the impressive success of statins in vascular
disease trials has made it much more difficult to study any
potential drawbacks to aggressive LDL lowering.
Finally, such a trial might address the interesting
question of whether achievement of very low LDL levels
would obviate the need to aggressively modify other risk
factors. If, as Roberts (8) suggested some time ago, LDL
is the necessary substrate for atherogenesis, without
which atherosclerosis does not progress, then achieve-
ment of extremely low LDL levels might be worthwhile,
particularly if it can be done without significant risk. In
this regard, it is interesting that in both the TNT
(Treating to New Targets) and JUPITER (Justification
for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin) studies (2,3), high-density li-
poprotein levels ceased to be predictors of vascular risk in
those with very low LDL levels.
In short, whether the benefits of statin therapy persist
even at very low LDL levels can only be answered in a
placebo-controlled clinical trial. Based on these and other
similar findings, it is a trial worth considering.
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